PROK Company Profile and Key Details

ProKidney Corp. (NASDAQ:PROK) closed at $1.61 USD, gaining $0.19 (13.38%) from the previous close of $1.42. The stock is currently mid-range between its 52-week high and low $1.30 and $3.48. With a market capitalization of about $541.37 million, ProKidney Corp. is classified as a small-cap and shows higher-than-market volatility (beta ~1.72). Key stats such as the average daily volume over the past year has been around 1.24 million shares, in line with its 52-week average. Headquartered in Winston-Salem, NC, ProKidney Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bruce Culleton, the company employs approximately 231 people and listed since June 30, 2021. ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments.

ProKidney Corp. has 205.20 million shares outstanding. The public float is 156.76 million shares, elevated short interest at 13.79% of float. This equals 20.91 million shares. The short ratio is 13.13 days. Institutional investors hold 46.87% of the float. Insiders own 47.3%. Control Empresarial de Capitales S.A. de C.V. holds 73.84 million shares, Legorreta Pablo G. has 22.62 million shares and Cowen Aaron has 6.28 million shares. Over the past six months, insider transactions show net selling. They sold 81.93 thousand shares across 3 transactions.

Short-term trend indicators are bullishly aligned (SMA20 8.94%, SMA50 2.0%, SMA200 -0.11%). The stock’s 14-day RSI is 56.26 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.72% below its high and over 384.47% above its low. Average 10-day trading volume of 1.60 million shares is slightly above the 3-month average of 1.22 million, indicating heightened recent market interest.

Our AI price prediction model suggests that ProKidney Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.91%, with price expected at $1.37 by September 03, 2026, within a range of $1.25 to $1.49 3-Month Outlook: Projected rise of 380.75%, reaching $7.74 by November 18, 2026, with a range of $7.15 to $8.56. 1-Year Outlook: Projected loss of -36.02%, with price at $1.03 by August 20, 2027, within a range of $0.00 to $0.00.

ProKidney Corp. (NASDAQ:PROK) shares are flat -4.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ProKidney Corp. trading at a premium to the broader market with a P/E of -2.76. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.31, suggesting 602.48% upside. Our AI forecast model points to short-term weakness (-14.91% over two weeks), a medium-term rise (380.75% over three months), and a longer-term loss (-36.02% over one year), with expected trading ranges indicating moderate volatility.